Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 784Lung Neoplasms 346Ovarian Neoplasms 323Breast Neoplasms 279Fallopian Tube Neoplasms 159Triple Negative Breast Neoplasms 146Small Cell Lung Carcinoma 146Neoplasms 137Squamous Cell Carcinoma of Head and Neck 123Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 86Head and Neck Neoplasms 80Endometrial Neoplasms 77Uterine Cervical Neoplasms 72Esophageal Neoplasms 72Adenocarcinoma of Lung 71Neuroblastoma 55Central Nervous System Neoplasms 53Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Recurrence 48Brain Neoplasms 48Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Stomach Neoplasms 31

Interventions

Pemetrexed 3apatinib 2Paclitaxel 2Carboplatin 2tislelizumab 1pembrolizumab 1lenvatinib 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Non-squamous Non-small-cell Lung Cancer × Carboplatin × Clear all
NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 3 Recruiting
392 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

NCT04416035 2020-08-31

NSCLC

Zhejiang Teruisi Pharmaceutical Inc.

Phase 3 Unknown
608 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡